An interventional study of Single high dose vitamin D and Placebo in Covid19, Vitamin D Deficiency and Corona Virus Infection, sponsored by Prof. Dr. Jörg Leuppi. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Prof. Dr. Jörg Leuppi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.
Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 28th largest by enrollment of the 49 interventional ones that give a count, is one of 48 that started in 2020, is one of 16 with no phase, and was the 40th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:
Flurin Cathomas · Sites in Switzerland
Ages 18–65
Universitaire Ziekenhuizen KU Leuven · Sites in Switzerland, Belgium, Germany
Ages 18–70
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–120
Calmy Alexandra · Sites in Switzerland
Ages 16+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 21 · Phase 4 2
First in 2016; this study’s year is marked. 48 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 100 across the 49 interventional studies, 425 across the 47 observational. Of the 70 that completed or were terminated, 11 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 97 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. Jörg Leuppi is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Prof. Dr. Jörg Leuppi has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482138Universitaire Ziekenhuizen KU LeuvenDysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation | 2026-12-31 |
| NCT06716996Flurin CathomasRTMS for the Treatment of Post-COVID Associated Affective Symptoms | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies in COVID-19 with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The world is currently facing a pandemic with the coronavirus (SARS-CoV-2) which leads to the disease of COVID-19. Risk factors for a poor outcome of COVID-19 have so far been identified as older age and co-morbidity including chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) and current smoking status. Previous studies found, that vitamin D deficiency is more prevalent among patients with these risk factors. There are observational studies reporting independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating vitamin D metabolite) and susceptibility to acute respiratory tract infection.
Vitamin D substitution in patients with COVID-19 who show a vitamin D deficiency should therefore be investigated for efficacy and safety.
The study is designed as a randomized, placebo-controlled, double blind study. The objective of the study is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 treated under standardized conditions in hospital will recover faster when additionally treated with a single high dose of vitamin D compared to standard treatment only.
The world is currently experiencing a coronavirus (SARS-CoV-2) pandemic. The disease caused by infection with this virus is known as COVID-19. Risk factors for a poor outcome of COVID-19 have so far been found to include, older age and co-morbidity including chronic respiratory conditions and current smoking status. Previous studies found, that vitamin D deficiency is more prevalent among patients with these risk factors.
There are observational studies reporting independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating vitamin D metabolite) and susceptibility to acute respiratory tract infection. 25-hydroxyvitamin D supports induction of antimicrobial peptides in response to both viral and bacterial stimuli suggesting a potential mechanism by which vitamin D inducible protection against respiratory pathogens might be mediated. The clear functions of vitamin D in the immune system are difficult to define because the immune response is not a static process. The vitamin-D-receptor, which has also been detected in immunological cells, suggests that vitamin D can regulate some processes related to immunity. A further argument which supports a potential antiviral activity of vitamin D is the modulation of the inflammatory response. The release of pro-inflammatory cytokines by the influenza virus appeared to correlate with the severity of illness. The use of vitamin D as a prophylactic for influenza has shown promise in prevention of illness and reduction of secondary asthma in children. Inadequate vitamin D status is associated with susceptibility to upper respiratory infections in patients with chronic obstructive pulmonary disease (COPD). In the ViDiCo-trial vitamin D supplementation protected against moderate or severe exacerbation, but not upper respiratory infection, in patients with COPD. A further study retrospectively examined data from 108 patients with acute respiratory distress syndrome (ARDS) for whom a vitamin D status was available at the time of diagnosis revealed that over 95% of these patients had vitamin D deficiency. When examined according to quarterly of serum 25- hydroxyvitamin D, a consistent inverse relationship between serum 25-hydroxyvitamin D and length of hospital and ICU stay among survivors was observed. Vitamin D substitution in patients with COVID-19 who show a vitamin D deficiency should therefore be investigated for efficacy and safety.
For this purpose the investigators designed a randomized, placebo controlled double blind trial to test the hypothesis hypothesis that a single high dose of vitamin D in addition to standard treatment improves the recovery period positively in patients with COVID-19 and vitamin D deficiency compared to standard treatment only. That means, that the time of recovery is shorter in the single high dose vitamin D group relative to standard treatment group only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D. The medication be administered orally
Drug: Single high dose vitamin D · Drug: Treatment as usual vitamin D
Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)
Drug: Placebo · Drug: Treatment as usual vitamin D
Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
Also known as: VITAMIN D3 oil 500 IU/drop
Patient receives a single dose of a placebo solution
Also known as: Oily placebo solution
Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
Also known as: Vitamin D3 solution 4000 IU/ml
Length of hospitalization
Overall duration of the hospitalization from day of admission until the day of discharge or fatality
Time frame: Administration to Discharge from hospital care (mean duration is between 14 and 22 days for Patients with COVID 19)
Need of intensive care
Did the patient need a intensive care treatment during the hospitalization (yes/no)
Time frame: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)
Lenght of the Intensive Care Treatment
Day of admission to ICU until discharge or fatality
Time frame: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)
Overall mortality
Percentage of patient died during hospitalization
Time frame: During the length of hospitalisation (mean duration is between 14 and 22 days for Patients with COVID-19)
Development of vitamin D levels
percentage of patients with 25-hydroxyvitamin D \> 50nmol/L (\>20ng/mL) at day 7 - The values of calcium, phosphorus, 24-hydroxyvitamin D, 1.25-dihydroxyvitamin D, parathyroid hormone.
Time frame: Day 1 (Baseline) and Day 7 after the first administration of the high dose vitamin D or the placebo and at discharge (mean hospital stay is between 14 and 22 days for Patients with COVID-19)
Development of sepsis
percentage of patients developing a sepsis
Time frame: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)
Complications due to COVID-19
We assess every other complications which occurs due to COVID-19
Time frame: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)
Blood pressure (BP)
The BP will be assessed daily in mmHg
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)
Heart rate
The heart rate will be assessed daily in bpm
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)
Peripheral oxygen saturation (SpO2)
The SpO2 will be assessed daily in %
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
Percentage of patients who require oxygen
Requirement for oxygen will be assessed daily (yes/no) if yes how many liters per minute
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
Breathing frequency
Breathing frequence will be assessed daily in breaths per minute
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
Glasgow Coma Scale (GCS)
GCS will be assessed daily 3 to 15 points. It describes the extent of impaired consciousness. 15 points means no impairment, 3 points means severe impairment of consciousness.
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
Percentage of patients are smokers, former smokers or lifelong non-smokers
Assessing the history of smoking in pack years (PY). the assessment will be made with the following options for answering Current smoker: Smoking for how many years? Cigarettes per day? Former smoker, how many years smoked? How many cigarettes per day Life-long non-smoker
Time frame: Assessing of the smoking Status at Basleine
Current Symptoms
Assessed in No/ Mild/ Moderate /Severe
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
Temperature
Temperature will be assessed daily in degrees celsius
Time frame: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)
Plan to share: No
Ran from Dec 2020 to primary completion in Aug 2021, 8 months.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 8 months is below that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. Jörg Leuppi